Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EBISC

Financiado

European Bank for induced pluripotent Stem Cells

EBiSC is designed to address the increasing demand by iPSC researchers for quality-controlled, disease-relevant research grade iPSC lines, data and cell services. Its goal is to demonstrate an operational banking and distribution... ver más

31/12/2017

JANSSEN PHARMACEUT...

34M€

Presupuesto del proyecto: 34M€

Líder del proyecto

JANSSEN PHARMACEUTICA NV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 22 Participantes

Financiación concedida El organismo FP6 notifico la concesión del proyecto el día 2017-12-31 No tenemos la información de la convocatoria

0% 100%

22 Participantes

JANSSEN PHARMACEUTICA NV

Lider

ISCIII

N.D. | Participante

Pfizer RD UK Limited

N.D. | Participante

KLINIKUM DER UNIVERSITAET ZU...

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

EASY-IPS a rapid and efficient method for generation of iPSC 150K€ Cerrado

BFU2009-13513 DERIVACION DE LINEAS CELULARES RECOMBINANTES HUMANAS ES/IPS... 424K€ Cerrado

hPSCreg human pluripotent stem cell registry - hPSCreg 1M€ Cerrado

SAF2009-07965 POTENCIAL CARDIOVASCULAR DE LAS CELULAS MADRE PLURIPOTENTES... 145K€ Cerrado

SAF2012-36143 INTERACCION FUNCIONAL ENTRE P73 Y P53, EN LA REGULACION DE L... 94K€ Cerrado

PTA2012-7109-I Generación de iPSCs como modelo de estudios de enfermedades... 36K€ Cerrado

Duración del proyecto: 47 meses Fecha Inicio: 2014-01-01
Fecha Fin: 2017-12-31

Líder del proyecto

JANSSEN PHARMACEUTICA NV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 34M€

Descripción del proyecto EBiSC is designed to address the increasing demand by iPSC researchers for quality-controlled, disease-relevant research grade iPSC lines, data and cell services. Its goal is to demonstrate an operational banking and distribution service of iPSC lines after 3 years and to establish subsequently for Europe a centralised, not-for-profit bank providing all qualified users with access to scalable, cost-efficient and customised products. The EBiSC Consortium including EFPIA partners boasts the leadership, scientific expertise, facilities, networks and experience to achieve these goals and, being representative of all stakeholders from tissue donors to clinical and academic iPSC researchers and industrial users, to respond appropriately to advances in science and society. Led by Pfizer Ltd and managed by Roslin Cells, the Consortium comprises 8 active participant iPSC Centres with clinical and patient networks, a global leader in industrial iPSC supply, international experts in iPSC science, biobanking, bioengineering and regenerative medicine, and scholars in law and ethics. The main facility will be at the Babraham Research Campus (Cambridge, UK) and will undertake cell expansion, QC and characterisation. The European Cell Culture Collection (ECACC) of Public Health England (Department of Health, UK) will coordinate cell line distribution. The Fraunhofer IBMT (Saarbrücken, Germany) will provide comprehensive operational back up. EBiSC’s capacity will be 10,000 cell lines; it will eventually process over 1,000 lines in annual sales. In a phased business strategy EBiSC will hot-start distribution of lines contributed by iPSC Centres in 2014, lines collected based on specified user demand, will reach full scale operations in 2016, and with extended funding will become self-sustaining as a not for profit banking operation by 2019. EBiSC will spearhead Europe in the international standardisation of iPSC banking by forging collaborative links with similar endeavours in the USA and Asia. Through market research, stakeholder engagement, incentives and training, EBiSC will promote wider participation and use, maximise the value of the research resource, and secure its longevity. EBiSC will promote iPSC technology and global iPSC banking, strengthen the competitiveness of European R&D, and enhance the health and wealth of nations.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores